Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ742879B2 - Antibody molecules to april and uses thereof - Google Patents
[go: Go Back, main page]

NZ742879B2 - Antibody molecules to april and uses thereof - Google Patents

Antibody molecules to april and uses thereof

Info

Publication number
NZ742879B2
NZ742879B2 NZ742879A NZ74287916A NZ742879B2 NZ 742879 B2 NZ742879 B2 NZ 742879B2 NZ 742879 A NZ742879 A NZ 742879A NZ 74287916 A NZ74287916 A NZ 74287916A NZ 742879 B2 NZ742879 B2 NZ 742879B2
Authority
NZ
New Zealand
Prior art keywords
april
april antibody
antibody
seq
amino acid
Prior art date
Application number
NZ742879A
Other versions
NZ742879A (en
Inventor
Hall Hedy Adari
Gregory Babcock
James R Myette
Boopathy Ramakrishnan
Zachary Holmes Shriver
Karthik Viswanathan
Andrew M Wollacott
Original Assignee
Visterra Inc
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Priority to NZ782617A priority Critical patent/NZ782617B2/en
Priority to NZ782606A priority patent/NZ782606B2/en
Priority claimed from PCT/US2016/063518 external-priority patent/WO2017091683A1/en
Publication of NZ742879A publication Critical patent/NZ742879A/en
Publication of NZ742879B2 publication Critical patent/NZ742879B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.

Claims (18)

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:
1. An anti-A PRoliferation Inducing Ligand (APRIL) antibody comprising a heavy chain variable domain comprising a heavy chain complementarity determining region (VH CDR) 1, a VH CDR2, 5 and a VH CDR3 and a light chain variable domain comprising a light chain complementarity determining region (VL CDR)1, a VL CDR2, and a VL CDR3, wherein: a) the VH CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 11; b) the VH CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12; c) the VH CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13; 10 d) the VL CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 280; e) the VL CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 285; and f) the VL CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, by the
2. Chothia numbering system. 15 2. The anti-APRIL antibody of claim 1 further comprising a constant region linked to the VH and or
3. The anti-APRIL antibody of claim 1 or claim 2, wherein the anti-APRIL antibody comprises: (a) a heavy chain constant region of IgG1, IgG2, IgG3, or IgG4; 20 (b) a light chain constant region of kappa or lambda light chain; or (c) both (a) and (b).
4. The anti-APRIL antibody of any one of claims 1–3, wherein the anti-APRIL antibody comprises a fragment crystallizable (Fc) region, wherein the Fc region comprises one or more mutations located 25 at the interface between the constant heavy chain (CH) 2 and CH3 domains.
5. A nucleic acid encoding the anti-APRIL antibody of any one of claims 1–4.
6. A vector comprising the nucleic acid of claim 5.
7. An isolated cell comprising the vector of claim 6.
8. A method of producing an anti-APRIL antibody, the method comprising culturing the isolated cell of claim 7, thereby producing the anti-APRIL antibody.
9. The method of claim 8, further comprising isolating or purifying the anti-APRIL antibody.
10. A composition comprising the anti-APRIL antibody of any one of claims 1–4 and a 5 pharmaceutically acceptable carrier.
11. A kit comprising the anti-APRIL antibody of any one of claims 1–4 or the composition of claim 10, and instructions to use the anti-APRIL antibody of any one of claims 1–4 or the composition of claim 10.
12. A container comprising the anti-APRIL antibody of any one of claims 1–4 or the composition of claim 10.
13. An anti-APRIL antibody conjugate, comprising the anti-APRIL antibody of any one of claims 1–4 15 conjugated to a substance.
14. The anti-APRIL antibody conjugate of claim 13, wherein the substance comprises a toxin, a moiety, a therapeutic drug, a radiation- emitting compound, a molecule of plant, fungal or bacterial origin, a biological protein, a protein toxin, a particle, a recombinant viral particle, a radioactive isotope, 20 or a combination thereof.
15. An anti-APRIL antibody derivative, comprising the anti-APRIL antibody of any one of claims 1– 4 derivatized to a functional molecule or one or more molecular entities. 25
16. The anti-APRIL antibody derivative of claim 15, wherein the functional molecule or the one or more molecular entities comprises a peptide, a protein, an antibody, a detectable agent, a toxin, a pharmaceutical agent, or a combination thereof.
17. Use of the anti-APRIL antibody of any one of claims 1–4, the composition of claim 10, the anti- 30 APRIL antibody conjugate of claim 13 or claim 14, or the anti-APRIL antibody derivative of claim 15 or claim 16 in the manufacture of a medicament for treating a disease or condition in a subject, wherein the disease or condition comprises IgA nephropathy.
18. An in vitro or ex vivo method of detecting an APRIL molecule, the method comprising contacting a cell or a sample from a subject with the anti-APRIL antibody of any one of claims 1–4 in vitro or ex vivo, thereby detecting the APRIL molecule.
NZ742879A 2016-11-23 Antibody molecules to april and uses thereof NZ742879B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ782617A NZ782617B2 (en) 2016-11-23 Antibody molecules to APRIL and uses thereof
NZ782606A NZ782606B2 (en) 2016-11-23 Antibody molecules to APRIL and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562259897P 2015-11-25 2015-11-25
US201662313684P 2016-03-25 2016-03-25
US201662399087P 2016-09-23 2016-09-23
US201662422848P 2016-11-16 2016-11-16
PCT/US2016/063518 WO2017091683A1 (en) 2015-11-25 2016-11-23 Antibody molecules to april and uses thereof

Publications (2)

Publication Number Publication Date
NZ742879A NZ742879A (en) 2025-06-27
NZ742879B2 true NZ742879B2 (en) 2025-09-30

Family

ID=

Similar Documents

Publication Publication Date Title
AU2019229076B2 (en) Anti-TIGIT antibodies and uses thereof
DK2493503T3 (en) DOSAGE SCHEDULE FOR THE ADMINISTRATION OF A CD19xCD3 bispecific antibody
CA2759733C (en) Anti-human ror1 antibodies
TWI640537B (en) PDGF receptor beta-binding polypeptide
CN112771161A (en) Antibodies specific for trophoblast cell surface antigen 2(TROP2)
HRP20210602T1 (en) BINDING MOLECULES BIND PD-L1 AND LAG-3
RU2017102514A (en) HUMANIZED ANTI-TAU-ANTIBODIES
JP2021524478A5 (en)
FI3380522T3 (en) Antibody molecules to april and uses thereof
HRP20200390T1 (en) Monoclonal antibodies against human b cell maturation antigen (bcma)
KR20150039798A (en) Blood brain barrier shuttle
HRP20200887T1 (en) MIXTURES FOR INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
WO2020136218A1 (en) Btn3a binding proteins and uses thereof
JP2018529635A5 (en)
HK1249427A1 (en) Arthritis treatment
TW202128131A (en) Recombinant anti-programmed cell death protein 1 and anti-cluster of differentiation antigen 137 bispecific antibody preparation and use thereof
FI4200018T3 (en) Anti-par-2 antibodies and methods of use thereof
CN112996815A (en) Human PD-L1 antibody
WO2020201828A1 (en) Anti-tauc3 antibodies and uses thereof
CN107474140B (en) PCSK9 specific binding protein MV072 and application thereof
AU2015252014B2 (en) Anti-human ror1 antibodies
NZ742879B2 (en) Antibody molecules to april and uses thereof
JP2023536630A5 (en)
CN107266575B (en) Binding protein of proprotein convertase subtilisin kexin type 9 and application thereof
CN113368232B (en) Multispecific antigen binding proteins and uses thereof